Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy

Ying, Jun; Zhou, Di; Gu, Tongjie; Huang, Jianda; Liu, Haijian

doi:10.1186/s12885-019-5490-y

Cited by 24 publications

(19 citation statements)

References 40 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were consistent with previous research on CRC [10,27]. Increasing studies have used FAR as an independent prognostic factor in patients with resectable ESCC, hepatocellular carcinoma, and advanced nonsmall cell lung cancer, and high levels of FAR can lead to high risk of recurrence and unfavorable OS [8,28,29]. Unfortunately, FAR was not an independent prognostic predictor for resectable GC in our study.…”

Section: Discussionsupporting

confidence: 91%

“…To date, several inflammation-based biomarkers, such as C-reactive protein, albumin, neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and Glasgow prognostic score (GPS), have been revealed as useful prognostic biomarkers in GC, colorectal cancer (CRC), breast cancer, and lung cancer [5][6][7]. In addition, high levels of fibrinogen-to-albumin ratio (FAR), a novel inflammation-based biomarker, are associated with poor outcomes in various cancers, including esophageal squamous cell carcinoma (ESCC), breast cancer, gallbladder cancer, and soft tissue sarcoma [8,9]. More recently, the fibrinogen-to-prealbumin ratio (FPR) was demonstrated to be an excellent diagnostic and prognostic biomarker for patients with CRC and a tool to identify individuals who can benefit from adjuvant chemotherapy treatment [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer

et al. 2020

View full text Add to dashboard Cite

Background: Chronic inflammation is considered as a hallmark of gastric cancer (GC) and plays a critical role in GC progression and metastasis. This study aimed to explore the prognostic values of preoperative fibrinogen-toprealbumin ratio (FPR), fibrinogen-to-albumin ratio (FAR), and novel FPR-FAR-CEA (FFC) score in patients with GC undergoing gastrectomy. Methods: A total of 273 patients with resectable GC were included in this retrospective study. We performed Kaplan-Meier and Cox regression analyses to assess the prognostic role of preoperative FPR, FAR, and FFC score in patients with GC and analyze their relationships with clinicopathological features. Results: Receiver operating characteristic curve (ROC) analysis revealed that the optimal cutoff values for FPR and FAR were 0.0145 and 0.0784, respectively. The FFC score had a higher area under the ROC curve than FAR and CEA. Elevated FPR (≥ 0.0145) and FAR (≥ 0.0784) were significantly associated with old age, large tumor size, tumor invasion depth, lymph nodes metastasis, advanced TNM stage, large Borrmann type, and anemia status. Kaplan-Meier analysis showed that high FPR, FAR, and FFC score were related to poor survival. Multivariate analyses indicated that FPR, FFC score, TNM stage, and tumor size were significant independent factors for survival. Conclusions: Preoperative FPR and FFC score could be used as prospective noninvasive prognostic biomarkers for resectable GC.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As a marker reflecting coagulation function nutritional and the inflammatory status of patients, several studies have used the fibrinogen-to-albumin ratio (FAR) or albumin-to-fibrinogen ratio (AFR) to evaluate the prognosis of various cancer patients, including those with GC, and have found that increased FAR or decreased AFR levels were associated with poor prognosis in cancer patients (12)(13)(14)(15)(16)(17). Another critical role of FAR or AFR is to assess the effect of the chemotherapy regimen in a particular population to guide the selection of an optimal therapy (18)(19)(20). However, there are currently few reports on the pretreatment FAR being used as a marker to predict progression-free survival (PFS) and overall survival (OS) in patients with GC undergoing first-line chemotherapy.…”

Section: Prognostic Value Of Fibrinogen-to-albumin Ratio In Patients mentioning

confidence: 99%

Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy

et al. 2020

View full text Add to dashboard Cite

The fibrinogen-to-albumin ratio (FAR), reflecting the systemic coagulation, nutritional and inflammation status of patients, has matured into a prognostic marker for several tumor types. However, only a few studies have assessed the utility of the FAR as a prognostic indicator in patients with advanced gastric cancer (GC) receiving first-line chemotherapy. In the present study, 273 patients with advanced GC who received first-line chemotherapy between January 2014 and January 2019 at the Cancer Hospital of China Medical University (Shenyang, China) were retrospectively analyzed. Using the cutoff values determined by receiver operating characteristic (ROC) analysis, the patients were divided into low-FAR (≤10.03) and high-FAR (>10.03), low-fibrinogen (<3.8 g/l) and high-fibrinogen (≥3.8 g/l), and low-albumin (<40.55 g/l) and high-albumin (≥40.55 g/l) groups. The associations of the pretreatment FAR and clinicopathological characteristics with progression-free survival (PFS) and overall survival (OS) were evaluated. In order to estimate the prognostic value of the FAR for patients with poor prognosis or normal fibrinogen and albumin levels, subgroup analyses were performed. The FAR had a higher area under the ROC curve (0.690; 95% CI: 0.628-0.752; P<0.001) compared with either fibrinogen or albumin alone, which are common indicators of coagulation, nutritional and inflammatory indices. A high FAR was significantly associated with a more advanced stage, peritoneal metastasis, increased CA72-4 levels and anemia (all P<0.05). On survival analysis, a low FAR was associated with a longer PFS and OS compared with a high FAR (202 vs. 130 days and 376 vs. 270 days, respectively; both P<0.001), while the hazard ratio (HR) and P-values of the FAR were lower compared with those of fibrinogen and albumin alone on multivariate analysis (PFS: HR= 0.638, 95% CI: 0.436-0.932, P= 0.020; OS: HR= 0.568, 95% CI: 0.394-0.819, P= 0.002). Subgroup analysis indicated that among patients with poor prognosis, including multiple metastases, TNM stage IV and abnormal CA72-4 levels, the FAR may be used as an accurate prognostic marker (all P<0.05), and may also reliably identify patients with poor prognosis among those with normal fibrinogen and albumin levels (all P<0.001). The FAR was indicated to be a valuable marker for predicting PFS and OS in patients with advanced GC receiving first-line chemotherapy and is superior to either fibrinogen or albumin alone.

show abstract

“…Cisplatin-based chemotherapy is considered as the first-line treatment for NSCLC. 13,14 Despite cisplatin-based chemotherapy is effective, development of drug resistance is a usual incidence during the course of cisplatin treatment. 15,16 It is urgent for us to explore useful approaches to reverse the resistance against cisplatin.…”

Section: Discussionmentioning

confidence: 99%

“…11,12 Nowadays, cisplatin-based chemotherapy is still used as the first-line treatment for NSCLC. 13,14 However, virtually all of the NSCLC cells eventually become resistant to cisplatin because of the long-term use of it. 15,16 Novel approaches are required to overcome the resistance of cisplatin in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

<p>MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway</p>

Lin¹,

Pan²,

Chen³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Although cisplatin is an effective chemotherapeutic drug that is commonly used for non-small-cell lung cancer (NSCLC) treatment, the drug resistance usually occurs during the long-term use of it. It is urgent to develop strategies to reduce the resistance of NSCLC cells to cisplatin. Methods: Cisplatin-resistant NSCLC cell lines (PC9/R and A549/R) were acquired through long-term exposure of PC9 and A549 cells to cisplatin. QRT-PCR analysis was performed to compare the expression of miR-140 between routine NSCLC cells and cisplatin-resistant NSCLC cells. CCK-8 assay was used to evaluate the effect of miR-140 on the sensitivity of PC9/R and A549/R to cisplatin. Western blot assay and luciferase reporter assay were used to confirm the regulation of miR-140 on SIRT1. Western blot and flow cytometry analysis were performed to evaluate the effect of miR-140 on the apoptosis pathway induced by cisplatin. Results: PC9/R and A549/R exhibited obviously lower sensitivity compared to their parental PC9 and A549 cells, respectively. Furthermore, PC9/R and A549/R cells expressed significantly lower levels of miR-140 compared to their parental PC9 and A549 cells, respectively. However, transfection with miR-140 mimics significantly resensitized the PC9/R and A549/R to cisplatin-induced cytotoxicity. In the mechanism research, we confirmed that SIRT1 was overexpressed and was targeted by miR-140 in PC9/R and A549/R. Furthermore, overexpression of SIRT1 was responsible for the resistance to cisplatin in PC9/ R and A549/R cells. Transfection with miR-140 was able to inhibit the expression of SIRT1 and thus inhibited the SIRT1/ROS/JNK pathway. As a result, the PC9/R and A549/R cells restored the sensitivity to cisplatin-induced apoptosis. Conclusion: MiR-140 resensitizes cisplatin-resistant NSCLC cells to cisplatin treatment through the SIRT1/ROS/JNK pathway.

show abstract

Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy

Cited by 24 publications

References 40 publications

The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer

The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer

Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy

<p>MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway</p>

Contact Info

Product

Resources

About